Biofarma
http://www.biofarma.it
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biofarma
Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval
The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”
Almirall On Alert As Lebrikizumab Approval Date Approaches
The Barcelona-based group is confident that Lilly-partnered lebrikizumab has the potential to become a best-in-class treatment for atopic dermatitis and take market share from Sanofi’s blockbuster Dupixent.
J&J Taps Biological E For Up To 500m Coronavirus Vaccine Doses A Year
Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice